VF
PRLD icon

Virtu Financial’s Prelude Therapeutics PRLD Stock Holding History

Virtu Financial’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,607
Closed -$58K – 1953
2023
Q4 		$58K Buy
+13,607
New +$41.4K ﹤0.01% 1151
2023
Q2 		– Sell
-11,201
Closed -$64K – 1932
2023
Q1 		$64K Buy
+11,201
New +$68.3K 0.01% 1059
2021
Q4 		– Sell
-7,940
Closed -$248K – 2082
2021
Q3 		$248K Buy
+7,940
New +$257K 0.02% 806

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Virtu Financial's PRLD Position: Q1 2024 in Review

Virtu Financial sold out of Prelude Therapeutics (PRLD) in Q1 2024, closing a stake of 13,607 shares — an estimated $58K sold.

Virtu Financial first reported a position in PRLD in Q3 2021 and held it in 3 quarters. The position peaked at $248K in Q3 2021. 58 funds tracked by Wall St. Rank hold PRLD as of Q1 2024.

  • Virtu Financial reported no remaining Prelude Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 13,607 Prelude Therapeutics shares in Q1 2024, an estimated $58K.
  • Virtu Financial first reported a position in Prelude Therapeutics in Q3 2021 and held it in 3 quarters.
  • Virtu Financial's Prelude Therapeutics position peaked at $248K in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.